Your browser doesn't support javascript.
loading
Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
Yang, Xiaohong R; Rotunno, Melissa; Xiao, Yanzi; Ingvar, Christian; Helgadottir, Hildur; Pastorino, Lorenza; van Doorn, Remco; Bennett, Hunter; Graham, Cole; Sampson, Joshua N; Malasky, Michael; Vogt, Aurelie; Zhu, Bin; Bianchi-Scarra, Giovanna; Bruno, William; Queirolo, Paola; Fornarini, Giuseppe; Hansson, Johan; Tuominen, Rainer; Burdett, Laurie; Hicks, Belynda; Hutchinson, Amy; Jones, Kristine; Yeager, Meredith; Chanock, Stephen J; Landi, Maria Teresa; Höiom, Veronica; Olsson, Håkan; Gruis, Nelleke; Ghiorzo, Paola; Tucker, Margaret A; Goldstein, Alisa M.
Afiliação
  • Yang XR; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Rotunno M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Xiao Y; Division of Cancer Control and Population Studies, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Ingvar C; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Helgadottir H; Department of Surgery, Lund University Hospital, Lund, Sweden.
  • Pastorino L; Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital, Solna, Stockholm, Sweden.
  • van Doorn R; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
  • Bennett H; Genetics of Rare Cancers, IRCCS AOU San Martino-IST, Genoa, Italy.
  • Graham C; Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Sampson JN; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Malasky M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Vogt A; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Zhu B; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Bianchi-Scarra G; Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
  • Bruno W; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Queirolo P; Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
  • Fornarini G; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Hansson J; Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
  • Tuominen R; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
  • Burdett L; Genetics of Rare Cancers, IRCCS AOU San Martino-IST, Genoa, Italy.
  • Hicks B; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
  • Hutchinson A; Genetics of Rare Cancers, IRCCS AOU San Martino-IST, Genoa, Italy.
  • Jones K; Medical Oncology Unit, IRCCS AOU San Martino-IST, Genoa, Italy.
  • Yeager M; Medical Oncology Unit, IRCCS AOU San Martino-IST, Genoa, Italy.
  • Chanock SJ; Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital, Solna, Stockholm, Sweden.
  • Landi MT; Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital, Solna, Stockholm, Sweden.
  • Höiom V; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Olsson H; Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
  • Gruis N; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Ghiorzo P; Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
  • Tucker MA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Goldstein AM; Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Hum Genet ; 135(11): 1241-1249, 2016 Nov.
Article em En | MEDLINE | ID: mdl-27449771
ABSTRACT
The risk of pancreatic cancer (PC) is increased in melanoma-prone families but the causal relationship between germline CDKN2A mutations and PC risk is uncertain, suggesting the existence of non-CDKN2A factors. One genetic possibility involves patients having mutations in multiple high-risk PC-related genes; however, no systematic examination has yet been conducted. We used next-generation sequencing data to examine 24 putative PC-related genes in 43 PC patients with and 23 PC patients without germline CDKN2A mutations and 1001 controls. For each gene and the four pathways in which they occurred, we tested whether PC patients (overall or CDKN2A+ and CDKN2A- cases separately) had an increased number of rare nonsynonymous variants. Overall, we identified 35 missense variants in PC patients, 14 in CDKN2A+ and 21 in CDKN2A- PC cases. We found nominally significant associations for mismatch repair genes (MLH1, MSH2, MSH6, PMS2) in all PC patients and for ATM, CPA1, and PMS2 in CDKN2A- PC patients. Further, nine CDKN2A+ and four CDKN2A- PC patients had rare potentially deleterious variants in multiple PC-related genes. Loss-of-function variants were only observed in CDKN2A- PC patients, with ATM having the most pathogenic variants. Also, ATM variants (n = 5) were only observed in CDKN2A- PC patients with a family history that included digestive system tumors. Our results suggest that a subset of PC patients may have increased risk because of germline mutations in multiple PC-related genes.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Inibidor de Quinase Dependente de Ciclina p18 / Melanoma / Proteínas de Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Inibidor de Quinase Dependente de Ciclina p18 / Melanoma / Proteínas de Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article